Treatment efficacy seen in primary end points of itch response and Investigator’s Global Assessment response<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Oct. 26, 2023 (HealthDay News) — For patients with moderate-to-severe prurigo nodularis, nemolizumab improves symptoms, according to a study published in the Oct. 26 issue of the New England Journal of Medicine<\/em>.<\/p>\n Shawn G. Kwatra, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a phase 3, double-blind, randomized trial involving adults with moderate-to-severe prurigo nodularis. Participants were assigned to receive an initial 60-mg dose of nemolizumab followed by subcutaneous injections of 30 or 60 mg every four weeks for 16 weeks or matching placebo (183 and 91 patients, respectively).<\/p>\n The researchers found that at week 16, treatment efficacy was shown with respect to both primary end points (itch response and Investigator’s Global Assessment [IGA] response); a greater proportion of patients in the nemolizumab group than in the placebo group had an itch response (56.3 versus 20.9 percent) and an IGA response (score of 0 [clear] or 1 [almost clear]; 37.7 versus 11.0 percent). For the five key secondary end points, benefits were also observed: itch response at week 4, Peak Pruritus Numerical Rating Scale score of less than 2 at weeks 4 and 16, and improvement of 4 or more points on the sleep disturbance numerical rating scale at weeks 4 and 16.<\/p>\n “The results of this trial extend the efficacy and safety findings of nemolizumab from the phase 2 study in patients with prurigo nodularis,” the authors write.<\/p>\n The study was funded by Galderma, the manufacturer of nemolizumab.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n